Ad
Search
Generic filters
Filter by content type
Taxonomy terms

TGTX – TG Therapeutics Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

2.22

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 16.88

Low: 4

High: 40

Total Analysts: 8

Company Profile

TG Therapeutics, Inc. (TG) is a fully integrated, commercial stage biopharmaceutical company, which is focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. Its pipeline candidates include TG-1501 (Cosibelimab), TG-1701 (BTK inhibitor), TG-1801 (anti-CD47/anti-CD19 bispecific monoclonal antibody). Its UKONIQ (umbralisib) is developed for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed or refractory follicular lymphoma. It has three programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis and patients with chronic lymphocytic leukemia and several investigational medicines in Phase I clinical development. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses